Login
Codexis

Codexis

An enzyme engineering company supplying products to commercial customers and developing proteins for its own portfolio of clinical biologics.

Codexis was incorporated in 2002 by Maxygen to develop an enzyme engineering technology platform, completing a spin-off in 2010 as a separate publicly-listed company on the NASDAQ exchange. Today it has three major focus areas: supplying engineered enzymes to commercial customers in pharmaceutical manufacturing, food ingredient manufacturing, and other industrial areas; licensing its CodeEvolver technology package to companies interested in engineering enzymes in-house; and developing a clinical portfolio of biologics created from its technology platform. In 2018 the company expects to generate $60 million to $63 million in revenue for the full year, including $25 million to $28 million from products in commercial supply contracts.

Timeline

Currently, no events have been added to this timeline yet.
Be the first one to add some.

People

Name
Role
Related Golden topics

Gordon Sangster

Senior Vice President, CFO

Jim Lalonde

Senior Vice President of R&D

John Nichols

President, CEO

Michael Aldridge

Corporate and Strategic Development

Further reading

Author
Title
Link
Type

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services